Protara Therapeutics to Participate in Upcoming Investor Conferences
Thursday, February 19, 2026 2 min read
Key Takeaway: Protara Therapeutics, Inc. (Nasdaq: TARA) announced its participation in upcoming investor conferences, including the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the TD Cowen 46th Annual Health Care Conference. At these conferences, management will engage in fireside chats to discuss the company's initiatives and progress. Protara is dedicated to developing innovative therapies for cancer and rare diseases, with TARA-002 currently in Phase 2 trials for non-muscle invasive bladder cancer and lymphatic malformations.
Market Sentiment Analysis
POSITIVE FACTORS
Protara Therapeutics is actively participating in significant investor conferences.
The company is focused on developing transformative therapies for cancer and rare diseases.
Protara's lead candidate, TARA-002, is under evaluation in promising clinical trials.
Full Press Release Details
NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:
Oppenheimer 36th Annual Healthcare Life Sciences Conference. A fireside chat will take place virtually on Thursday, February 26 at 2:40 pm ET.
TD Cowen 46th Annual Health Care Conference. A fireside chat will take place on Tuesday, March 3 at 2:30 pm ET in Boston.
A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcasts will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.